PMID- 28293930
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 2092-7355 (Print)
IS  - 2092-7363 (Electronic)
IS  - 2092-7355 (Linking)
VI  - 9
IP  - 3
DP  - 2017 May
TI  - Anti-Interleukin-9 Antibody Increases the Effect of Allergen-Specific 
      Immunotherapy in Murine Allergic Rhinitis.
PG  - 237-246
LID - 10.4168/aair.2017.9.3.237 [doi]
AB  - PURPOSE: Interleukin (IL)-9 induces allergic responses; however, the roles of 
      anti-IL-9 antibody in the induction of tolerance remain unclear. This study 
      investigated the effects of anti-IL-9 antibody on oral tolerance (OT) in a mouse 
      model of allergic rhinitis (AR). METHODS: BALB/c mice were divided into 4 groups: 
      the control, AR, OT, and OT with anti-IL-9 antibody (OT+IL9AB) groups. Ovalbumin 
      (OVA) was used for sensitization and challenge. Mice in the OT and OT+IL9AB 
      groups were fed OVA for immunotherapy. During immunotherapy, OT+IL9AB mice were 
      injected with anti-IL-9 antibody. Allergic symptoms, tissue eosinophil counts, 
      and serum OVA-specific immunoglobulin E (IgE) were measured. The mRNA expressions 
      of cytokines and transcription factors of T cells of nasal mucosa were determined 
      by real-time polymerase chain reaction (PCR). The protein levels of GATA3, 
      ROR-gammat, and Foxp3 in nasal mucosa were determined by Western blot. 
      CD4(+)CD25(+)Foxp3(+) T cells in the spleen were analyzed by flow cytometry. RESULTS: 
      Administration of anti-IL-9 antibody decreased allergic symptoms, OVA-specific 
      IgE levels, and eosinophil counts. In addition, it inhibited T-helper (Th) 2 
      responses, but had no effect on Th1 responses. Protein levels of ROR-gammat and mRNA 
      levels of PU.1 and ROR-gammat were reduced by anti-IL-9 antibody. Anti-IL-9 antibody 
      increased Foxp3 and IL-10 mRNA expression, Foxp3 protein, and induction of 
      CD4(+)CD25(+)Foxp3(+) T cells. CONCLUSIONS: Anti-IL-9 antibody decreased allergic 
      inflammation through suppression of Th2 and Th17 cells. Anti-IL-9 antibody 
      enhanced the tolerogenic effects of regulatory T cells. These results suggest 
      that anti-IL-9 antibody might represent a potential therapeutic agent for 
      allergen immunotherapy in patients with uncontrolled allergic airway disease.
CI  - Copyright (c) 2017 The Korean Academy of Asthma, Allergy and Clinical Immunology . 
      The Korean Academy of Pediatric Allergy and Respiratory Disease
FAU - Shin, Ji Hyeon
AU  - Shin JH
AD  - Department of Otolaryngology-Head and Neck Surgery, College of Medicine, The 
      Catholic University of Korea, Seoul, Korea.
FAU - Kim, Do Hyun
AU  - Kim DH
AD  - Department of Otolaryngology-Head and Neck Surgery, College of Medicine, The 
      Catholic University of Korea, Seoul, Korea.
FAU - Kim, Boo Young
AU  - Kim BY
AD  - Department of Otolaryngology-Head and Neck Surgery, College of Medicine, The 
      Catholic University of Korea, Seoul, Korea.
FAU - Kim, Sung Won
AU  - Kim SW
AD  - Department of Otolaryngology-Head and Neck Surgery, College of Medicine, The 
      Catholic University of Korea, Seoul, Korea.
FAU - Hwang, Se Hwan
AU  - Hwang SH
AD  - Department of Otolaryngology-Head and Neck Surgery, College of Medicine, The 
      Catholic University of Korea, Seoul, Korea.
FAU - Lee, Joohyung
AU  - Lee J
AD  - Department of Otolaryngology-Head and Neck Surgery, College of Medicine, The 
      Catholic University of Korea, Seoul, Korea.
FAU - Kim, Soo Whan
AU  - Kim SW
AD  - Department of Otolaryngology-Head and Neck Surgery, College of Medicine, The 
      Catholic University of Korea, Seoul, Korea. kshent@catholic.ac.kr.
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - Allergy Asthma Immunol Res
JT  - Allergy, asthma & immunology research
JID - 101518382
PMC - PMC5352575
OTO - NOTNLM
OT  - Allergic rhinitis
OT  - interleukin-9
OT  - mouse
OT  - oral tolerance
OT  - regulatory T cells
COIS- There are no financial or other issues that might lead to conflict of interest.
EDAT- 2017/03/16 06:00
MHDA- 2017/03/16 06:01
PMCR- 2017/05/01
CRDT- 2017/03/16 06:00
PHST- 2016/04/20 00:00 [received]
PHST- 2016/10/12 00:00 [revised]
PHST- 2016/10/14 00:00 [accepted]
PHST- 2017/03/16 06:00 [entrez]
PHST- 2017/03/16 06:00 [pubmed]
PHST- 2017/03/16 06:01 [medline]
PHST- 2017/05/01 00:00 [pmc-release]
AID - 9.237 [pii]
AID - 10.4168/aair.2017.9.3.237 [doi]
PST - ppublish
SO  - Allergy Asthma Immunol Res. 2017 May;9(3):237-246. doi: 
      10.4168/aair.2017.9.3.237.